Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis

Vaccine

Volumn 28, Issue 44, 2010, Pages 7146-7154

  Durantez, Maika ^a   Fayolle, Catherine ^b,c   Casares, Noelia ^a   Belsue, Virginia ^a   Riezu Boj, José I ^a   Sarobe, Pablo ^a   Prieto, Jesús ^a,d   Borrás Cuesta, Francisco ^a   Leclerc, Claude ^b,c   Lasarte, Juan J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b INSTITUT PASTEUR   (France)

^c INSERM   (France)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antigen targeting; Dendritic cells; Peptides; T cells; Vaccination

Indexed keywords

ALPHA MODULIN; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GAMMA MODULIN; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; LIGAND; PEPTIDE DERIVATIVE; PEPTIDOGLYCAN; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN E7; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; BINDING COMPETITION; CANCER THERAPY; CONTROLLED STUDY; COVALENT BOND; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG SYNTHESIS; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNOMODULATION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS EPIDERMIDIS; TUMOR REGRESSION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BACTERIAL TOXINS; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS E7 PROTEINS; POLY I-C; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAPHYLOCOCCUS EPIDERMIDIS; TOLL-LIKE RECEPTOR 2;

EID: 77957785747     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.070     Document Type: Article

References (34)

1. Townsend A., Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 1989, 7:601-624.
2. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449(7161):419-426.
3. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711.
4. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006, 6(6):476-483.
5. Lasarte J.J., Casares N., Gorraiz M., Hervas-Stubbs S., Arribillaga L., Mansilla C., et al. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J Immunol 2007, 178(2):748-756.
6. Cuadros C., Lopez-Hernandez F.J., Dominguez A.L., McClelland M., Lustgarten J. Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 2004, 72(5):2810-2816.
7. Tighe H., Takabayashi K., Schwartz D., Marsden R., Beck L., Corbeil J., et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 2000, 30(7):1939-1947.
8. LeibundGut-Landmann S., Gross O., Robinson M.J., Osorio F., Slack E.C., Tsoni S.V., et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007, 8(6):630-638.
9. Ahonen C.L., Doxsee C.L., McGurran S.M., Riter T.R., Wade W.F., Barth R.J., et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 2004, 199(6):775-784.
10. Wen T., Bukczynski J., Watts T.H. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol 2002, 168(10):4897-4906.
11. Ahlers J.D., Belyakov I.M., Berzofsky J.A. Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr Mol Med 2003, 3(3):285-301.
12. Binder R.J., Srivastava P.K. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol 2005, 6(6):593-599.
13. Bonifaz L.C., Bonnyay D.P., Charalambous A., Darguste D.I., Fujii S., Soares H., et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004, 199(6):815-824.
14. Delneste Y., Magistrelli G., Gauchat J., Haeuw J., Aubry J., Nakamura K., et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 2002, 17(3):353-362.
15. Fayolle C., Sebo P., Ladant D., Ullmann A., Leclerc C. In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes. J Immunol 1996, 156(12):4697-4706.
16. Guermonprez P., Fayolle C., Rojas M.J., Rescigno M., Ladant D., Leclerc C. In vivo receptor-mediated delivery of a recombinant invasive bacterial toxoid to CD11c+CD8 alpha-CD11bhigh dendritic cells. Eur J Immunol 2002, 32(11):3071-3081.
17. Sancho D., Mourao-Sa D., Joffre O.P., Schulz O., Rogers N.C., Pennington D.J., et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest 2008, 118(6):2098-2110.
18. Kaisho T., Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002, 1589(1):1-13.
19. Mehlin C., Headley C.M., Klebanoff S.J. An inflammatory polypeptide complex from Staphylococcus epidermidis: isolation and characterization. J Exp Med 1999, 189(6):907-918.
20. Otto M., O'Mahoney D.S., Guina T., Klebanoff S.J. Activity of Staphylococcus epidermidis phenol-soluble modulin peptides expressed in Staphylococcus carnosus. J Infect Dis 2004, 190(4):748-755.
21. Hajjar A.M., O'Mahony D.S., Ozinsky A., Underhill D.M., Aderem A., Klebanoff S.J., et al. Cutting edge: functional interactions between toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J Immunol 2001, 166(1):15-19.
22. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar RP, de Jongh BM, Drijfhout JW, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993, 23(9):2242-2249.
23. Cerny A., McHutchison J.G., Pasquinelli C., Brown M.E., Brothers M.A., Grabscheid B., et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995, 95(2):521-530.
24. Borras-Cuesta F., Golvano J., Sarobe P., Lasarte J.J., Prieto I., Szabo A., et al. Insights on the amino acid side-chain interactions of a synthetic T-cell determinant. Biologicals 1991, 19(3):187-190.
25. Zabala M., Lasarte J.J., Perret C., Sola J., Berraondo P., Alfaro M., et al. Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J Hepatol 2007, 47(6):807-815.
26. Mouries J., Moron G., Schlecht G., Escriou N., Dadaglio G., Leclerc C. Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood 2008, 112(9):3713-3722.
27. Uronen-Hansson H., Allen J., Osman M., Squires G., Klein N., Callard R.E. Toll-like receptor 2 (TLR2) and TLR4 are present inside human dendritic cells, associated with microtubules and the Golgi apparatus but are not detectable on the cell surface: integrity of microtubules is required for interleukin-12 production in response to internalized bacteria. Immunology 2004, 111(2):173-178.
28. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997, 185(12):2043-2051.
29. Umezawa K., Weinstein I.B., Shaw W.V. Staphylococcal delta-hemolysin inhibits cellular binding of epidermal growth factor and induces arachidonic acid release. Biochem Biophys Res Commun 1980, 94(2):625-629.
30. Bonifaz L., Bonnyay D., Mahnke K., Rivera M., Nussenzweig M.C., Steinman R.M. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002, 196(12):1627-1638.
31. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413(6857):732-738.
32. Honda K., Yanai H., Takaoka A., Taniguchi T. Regulation of the type I IFN induction: a current view. Int Immunol 2005, 17(11):1367-1378.
33. Hervas-Stubbs S., Olivier A., Boisgerault F., Thieblemont N., Leclerc C. TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help. Blood 2007, 109(12):5318-5326.
34. Birkbeck T.H., Whitelaw D.D. Immunogenicity and molecular characterisation of staphylococcal delta haemolysin. J Med Microbiol 1980, 13(2):213-221.